Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Phase 2 Active not recruiting 53 enrolled University of Chicago

NaSingle-groupOpen-labelTreatment

Summary

This is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.

Timeline

Start: 2019-11-25
Primary completion: 2023-03-30
Completion: 2026-09-30

Publications

Ntekim AI, Ibraheem A, Sofoluwe AA, Kotila O, Babalola C, Karrison T, Olopade CO. ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol. JCO Glob Oncol. 2020 Jul;6:983-990. doi: 10.1200/GO.20.00043.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	—	Intravenous
Subject	Trastuzumab	Monoclonal antibody	—	Subcutaneous
Background	Cyclophonsphamide	Unknown	—	Intravenous
Background	Epirubicin	Small molecule	—	Intravenous
Background	Letrozole	Other / unclassified	—	—
Background	Tamoxifen	Small molecule	—	—
Background	fluorouracil	Small molecule	—	Intravenous

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Summary

Timeline

Publications

Drugs

Indications